

Marka van Blitterswijk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3858317/publications.pdf>

Version: 2024-02-01

77
papers

7,596
citations

66234

42
h-index

76769

74
g-index

81
all docs

81
docs citations

81
times ranked

8092
citing authors

#	ARTICLE	IF	CITATIONS
1	Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS. <i>Neuron</i> , 2013, 77, 639-646.	3.8	962
2	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
3	Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. <i>Acta Neuropathologica</i> , 2013, 126, 829-844.	3.9	506
4	Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. <i>Nature Neuroscience</i> , 2015, 18, 1175-1182.	7.1	330
5	Evidence for an oligogenic basis of amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2012, 21, 3776-3784.	1.4	307
6	Detection of long repeat expansions from PCR-free whole-genome sequence data. <i>Genome Research</i> , 2017, 27, 1895-1903.	2.4	277
7	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. <i>Acta Neuropathologica</i> , 2015, 130, 77-92.	3.9	267
8	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 978-988.	4.9	232
9	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1037-1042.	9.4	218
10	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	179
11	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Nature Communications</i> , 2016, 7, 11253.	5.8	174
12	How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia. <i>Current Opinion in Neurology</i> , 2012, 25, 689-700.	1.8	169
13	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2011, 70, 964-973.	2.8	168
14	Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. <i>Neurology</i> , 2011, 76, 2066-2072.	1.5	151
15	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. <i>Acta Neuropathologica</i> , 2014, 127, 397-406.	3.9	133
16	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. <i>Journal of Medical Genetics</i> , 2014, 51, 419-424.	1.5	118
17	Primary lateral sclerosis: consensus diagnostic criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 373-377.	0.9	118
18	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. <i>Journal of Clinical Investigation</i> , 2020, 130, 6080-6092.	3.9	117

#	ARTICLE	IF	CITATIONS
19	Spt4 selectively regulates the expression of <i>C9orf72</i> sense and antisense mutant transcripts. <i>Science</i> , 2016, 353, 708-712.	6.0	116
20	Long-read sequencing across the <i>C9orf72</i> "GGGGCC"™ repeat expansion: implications for clinical use and genetic discovery efforts in human disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 46.	4.4	111
21	Novel clinical associations with specific <i>C9ORF72</i> transcripts in patients with repeat expansions in <i>C9ORF72</i> . <i>Acta Neuropathologica</i> , 2015, 130, 863-876.	3.9	104
22	VCP mutations in familial and sporadic amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2012, 33, 837.e7-837.e13.	1.5	103
23	Repetitive element transcripts are elevated in the brain of <i>C9orf72</i> ALS/FTLD patients. <i>Human Molecular Genetics</i> , 2017, 26, 3421-3431.	1.4	101
24	Hexanucleotide repeat expansions in <i>C9ORF72</i> in the spectrum of motor neuron diseases. <i>Neurology</i> , 2012, 79, 878-882.	1.5	100
25	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
26	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
27	Cerebellar <i>c9RAN</i> proteins associate with clinical and neuropathological characteristics of <i>C9ORF72</i> repeat expansion carriers. <i>Acta Neuropathologica</i> , 2015, 130, 559-573.	3.9	89
28	<i>C9ORF72</i> repeat expansions in cases with previously identified pathogenic mutations. <i>Neurology</i> , 2013, 81, 1332-1341.	1.5	84
29	In-depth clinico-pathological examination of RNA foci in a large cohort of <i>C9ORF72</i> expansion carriers. <i>Acta Neuropathologica</i> , 2017, 134, 255-269.	3.9	76
30	Ataxin-2 as potential disease modifier in <i>C9ORF72</i> expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	1.5	74
31	TYROBP genetic variants in early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 48, 222.e9-222.e15.	1.5	69
32	Prosaposin is a regulator of progranulin levels and oligomerization. <i>Nature Communications</i> , 2016, 7, 11992.	5.8	68
33	Paraoxonase gene mutations in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2010, 68, 102-107.	2.8	67
34	TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 446-451.	2.3	66
35	Genetic modifiers in carriers of repeat expansions in the <i>C9ORF72</i> gene. <i>Molecular Neurodegeneration</i> , 2014, 9, 38.	4.4	63
36	RNA processing pathways in amyotrophic lateral sclerosis. <i>Neurogenetics</i> , 2010, 11, 275-290.	0.7	61

#	ARTICLE	IF	CITATIONS
37	<i>C9orf72</i> -derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. <i>Science Advances</i> , 2021, 7, .	4.7	57
38	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Neuron</i> , 2021, 109, 448-460.e4.	3.8	56
39	Genetic Overlap between Apparently Sporadic Motor Neuron Diseases. <i>PLoS ONE</i> , 2012, 7, e48983.	1.1	55
40	Jump from Pre-mutation to Pathologic Expansion in <i>C9orf72</i> . <i>American Journal of Human Genetics</i> , 2015, 96, 962-970.	2.6	50
41	VAPB and <i>C9orf72</i> mutations in 1 familial amyotrophic lateral sclerosis patient. <i>Neurobiology of Aging</i> , 2012, 33, 2950.e1-2950.e4.	1.5	47
42	Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. <i>Neurobiology of Aging</i> , 2012, 33, 1016.e1-1016.e7.	1.5	46
43	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1236.	4.5	46
44	Mutational analysis of TARDBP in neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2011, 32, 2096-2099.	1.5	43
45	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. <i>Alzheimer's and Dementia</i> , 2020, 16, 118-130.	0.4	43
46	Neuroprotective Effect of Oligodendrocyte Precursor Cell Transplantation in a Long-Term Model of Periventricular Leukomalacia. <i>American Journal of Pathology</i> , 2009, 175, 2332-2342.	1.9	41
47	Identical twins with the <i>C9orf72</i> repeat expansion are discordant for ALS. <i>Neurology</i> , 2014, 83, 1476-1478.	1.5	40
48	Extensive transcriptomic study emphasizes importance of vesicular transport in <i>C9orf72</i> expansion carriers. <i>Acta Neuropathologica Communications</i> , 2019, 7, 150.	2.4	40
49	Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of <i>C9orf72</i> expansion carriers. <i>Molecular Neurodegeneration</i> , 2020, 15, 7.	4.4	34
50	Unaffected mosaic <i>C9orf72</i> case. <i>Neurology</i> , 2018, 90, e323-e331.	1.5	33
51	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	32
52	Progressive amnesic dementia, hippocampal sclerosis, and mutation in <i>C9ORF72</i> . <i>Acta Neuropathologica</i> , 2013, 126, 545-554.	3.9	30
53	<i>TMEM106B</i> haplotypes have distinct gene expression patterns in aged brain. <i>Molecular Neurodegeneration</i> , 2018, 13, 35.	4.4	30
54	Novel causal genes and disease modifiers. <i>Nature Reviews Neurology</i> , 2013, 9, 63-64.	4.9	28

#	ARTICLE	IF	CITATIONS
55	Expanded C9ORF72 Hexanucleotide Repeat in Depressive Pseudodementia. <i>JAMA Neurology</i> , 2014, 71, 775.	4.5	28
56	Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 502-509.	0.9	28
57	Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 430-438.	2.3	27
58	Profilin-1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 463-469.	1.1	25
59	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. <i>Experimental Neurology</i> , 2015, 271, 241-250.	2.0	25
60	C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. <i>Experimental Neurology</i> , 2016, 277, 171-177.	2.0	21
61	Characterization of FUS Mutations in Amyotrophic Lateral Sclerosis Using RNA-Seq. <i>PLoS ONE</i> , 2013, 8, e60788.	1.1	21
62	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1782-1796.	1.7	20
63	Excess of Rare Damaging TUBA4A Variants Suggests Cytoskeletal Defects in ALS. <i>Neuron</i> , 2014, 84, 241-243.	3.8	18
64	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. <i>Brain</i> , 2021, 144, 1082-1088.	3.7	17
65	C9orf72 repeats compromise nucleocytoplasmic transport. <i>Nature Reviews Neurology</i> , 2015, 11, 670-672.	4.9	12
66	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. <i>Neurology: Genetics</i> , 2017, 3, e161.	0.9	12
67	Rare and common paraoxonase gene variants in amyotrophic lateral sclerosis patients. <i>Neurobiology of Aging</i> , 2012, 33, 1845.e1-1845.e3.	1.5	11
68	Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis. <i>Neurology: Genetics</i> , 2022, 8, e654.	0.9	10
69	UBQLN2 in familial amyotrophic lateral sclerosis in the Netherlands. <i>Neurobiology of Aging</i> , 2012, 33, 2233.e7-2233.e8.	1.5	9
70	Mutations in the TRPV4 Gene Are Not Associated With Sporadic Progressive Muscular Atrophy. <i>Archives of Neurology</i> , 2012, 69, 790-1.	4.9	6
71	Preface: promoting research in PLS: current knowledge and future challenges. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 1-2.	1.1	6
72	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. <i>Brain</i> , 2022, 145, 2472-2485.	3.7	6

#	ARTICLE	IF	CITATIONS
73	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
74	Mutational analysis of TARDBP in Parkinson's disease. Neurobiology of Aging, 2013, 34, 1517.e1-1517.e3.	1.5	3
75	Clinical variability and additional mutations in amyotrophic lateral sclerosis patients with p.<scp>N</scp>352<scp>S</scp> mutations in <scp><i>TARDBP</i></scp>. Neuropathology and Applied Neurobiology, 2014, 40, 356-358.	1.8	1
76	ALS-FTD Complex Disorder due to <i>C9ORF72</i> Gene Mutation: Description of First Polish Family. European Neurology, 2014, 72, 64-71.	0.6	1
77	Repeat expansions in myoclonic epilepsy. Nature Genetics, 2018, 50, 477-478.	9.4	0